Congress needs to give the U.S. Health Resources and Services Administration (HRSA) comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program, the Biden administration said yesterday in its proposed budget—although it did so without saying the words “contract pharmacy.”
The administration called for 340B legislation in its fiscal 2023 budget request for HRSA. HRSA has been asking Congress without success since the Obama administration for general rulemaking authority over the 340B program. It asked for that authority again yesterday. HRSA also repeated its request, made for the first time in last year’s proposed budget, for authority to audit covered entities about how they use net income derived from 340B drug purchases, and to require entities to report how much money they make through 340B and how they use those revenues to HRSA.
Congress needs to give the U.S. Health Resources and Services Administration (HRSA) comprehensive regulatory authority over the 340B program to resolve the dispute over 340B contract pharmacy program, the Biden administration said yesterday in its proposed budget—although it did so without saying the words “contract pharmacy.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
